Publicaciones

Paauw JD, Borders H, Ingalls N, Boomstra S, Lambke S, Fedeson B, Goldsmith A, Davis AT.
The Incidence of PICC Line-Associated Thrombosis With and Without the Use of Prophylactic Anticoagulants.
JPEN J Parenter Enteral Nutr 2008 July-August;32(4):443-447.

Kakkar AK, Brenner B, Dahl OE, et al, for the RECORD2 investigators.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled study.
The Lancet 2008; 372:31-39

Fulco PP, Zingone MM, Higginson RT.
Possible antiretroviral therapy-warfarin drug interaction.
Pharmacotherapy 2008 Jul;28(7):945-9.

Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA; on behalf of the EACTS Audit and Guidelines Committee.
Guideline on antiplatelet and anticoagulation management in cardiac surgery.
Eur J Cardiothorac Surg 2008 Jul;34(1):73-92. Epub 2008 Mar 28.

Verheugt FW.
Long-term anticoagulation in patients with coronary disease, and future developments.
Curr Opin Cardiol 2008 Jul;23(4):315-9

Douen AG, Sabih M, Pageau N.
Thrombus detection by echocardiography in patients with acute ischemic stroke and chronic or new-onset atrial fibrillation.
J Stroke Cerebrovasc Dis 2008 Jul-Aug;17(4):208-11.

Beri A, Punnam SR.
Anticoagulation in Patients with Acute Ischemic Stroke and Atrial Fibrillation-a Balance of Risks and Benefits.
Cardiovasc Drugs Ther 2008 Jul 21. [Epub ahead of print]

Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, Bono F, Herbert JM.
Reversible biotinylated oligosaccharides. A new approach for a better management of anticoagulant therapy.
J Thromb Haemost 2008 Jul 19. [Epub ahead of print]

Barnes GD, Froehlich JB.
Anticoagulation: where we are and where we need to go.
J Thromb Thrombolysis 2008 Jul 18. [Epub ahead of print]

Manzano-Fernández S, Pastor FJ, Marín F, Cambronero F, Caro C, Pascual-Figal DA, Garrido IP, Pinar E, Valdés M, Lip GY.
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing.
Chest 2008 Jul 18. [Epub ahead of print]

Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ.
Low-Molecular-Weight Heparins are superior to Vitamin K Antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review.
J Exp Clin Cancer Res 2008 Jul 18;27(1):21. [Epub ahead of print]

Khoobiar S, Mejevoi N, Kaid K, Boiangiu C, Setty S, Tanwir A, Khalid K, Cohen M.
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
J Thromb Thrombolysis 2008 Jul 18. [Epub ahead of print]

Collen JF, Jackson JL, Shorr AF, Moores LK.
Prevention of venous thromboembolism in neurosurgery: a meta-analysis.
Chest 2008 Jul 18. [Epub ahead of print]

Sandercock PA, Counsell C, Tseng MC.
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
Cochrane Database Syst Rev 2008 Jul 16;(3):CD000119.

Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, Ntita K, Salmistraro G, Frangos C, Rossi F, Cordova R, Franz F, Zucchetta P, Kontothanassis D, Andreozzi GM; KANT (Knee Arthroscopy Nadroparin Thromboprophylaxis) Study Group.
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.
Ann Intern Med 2008 Jul 15;149(2):73-82

Audebert HJ, Schenk B, Tietz V, Schenkel J, Heuschmann PU.
Initiation of Oral Anticoagulation after Acute Ischaemic Stroke or Transient Ischaemic Attack: Timing and Complications of Overlapping Heparin or Conventional Treatment.
Cerebrovasc Dis 2008 Jul 15;26(2):171-177. [Epub ahead of print]

Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, Gonzales NR, Noser EA, Illoh K, Grotta JC.
Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge?
Arch Neurol 2008 Jul 14. [Epub ahead of print]

Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
Blood 2008 Jul 11. [Epub ahead of print]

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
N Engl J Med. 2008; 358(26):2776-86.

Bottaro FJ, Elizondo MC, Doti C, Bruetman JE, Perez Moreno PD, Bullorsky EO, Ceresetto JM.
Efficacy of extended thrombo-prophylaxis in major abdominal surgery: What does the evidence show? A meta-analysis.
Thromb Haemost 2008 Jun;99(6):1104-11.

Kakkar AK.
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer.
Clin Adv Hematol Oncol. 2008 Jun;6(6):416-417.

Eriksson BI, Borris LC, Friedman RJ, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
N Engl J Med 2008; 358:2765-2775.

Gandolfo C, Balestrino M, Burrone A, Del Sette M, Finocchi C.
Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy. : A prospective study of a consecutive stroke population admitted to a comprehensive stroke unit.
J Neurol 2008 Jun 20. [Epub ahead of print]

Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE.
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum (July/August).
Ann Pharmacother 2008 Jun 17. [Epub ahead of print]

Barantke M, Bonnemeier H.
Factor Xa inactivation in acute coronary syndrome.
Curr Pharm Des 2008;14(12):1186-90.

Franchini M, Mannucci PM
Interactions between genotype and phenotype in bleeding and thrombosis
Haematologica 2008; 93(5):649-52

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM.
Rivaroxaban, an oral direct factor Xa inhibitor.
Expert Opin Investig Drugs 2008 Jun;17(6):925-937.

Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A, Palareti G, Shiach C, Bryan S, Samama M, Burgess-Wilson M, Heagerty A, Maccallum P, Wright D, Jespersen J.
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage.
J Thromb Haemost 2008 Jun;6(6):935-43.

On behalf of the Botticelli investigators, the writing committee, Buller H, Deitchman D, Prins M, Segers A.
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study.
J Thromb Haemost 2008 Jun 6. [Epub ahead of print]

Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, Kornek G, Marosi C, Wagner O, Zielinski C, Pabinger I.
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS).
Blood. 2008 Jun 6. [Epub ahead of print]

Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, Nedjar H, Kahn SR.
Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery.
CMAJ 2008 Jun 3;178(12):1545-54.

Lip GY, Boos CJ.
Antithrombotic treatment in atrial fibrillation.
Postgrad Med J 2008 May;84(991):252-8.

O'Donnell M, Kearon C.
Perioperative management of oral anticoagulation.
Cardiol Clin 2008 May;26(2):299-309. PMID: 18407002 [PubMed - in process]

Bushnell BD, Anz AW, Bert JM.
Venous thromboembolism in lower extremity arthroscopy.
Arthroscopy 2008 May;24(5):604-11. Epub 2008 Jan 7.

Gray E, Mulloy B, Barrowcliffe TW.
Heparin and low-molecular-weight heparin.
Thromb Haemost 2008 May;99(5):807-18.

Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L.
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
Expert Opin Investig Drugs 2008 May;17(5):773-7.

Doggen CJ.
Thromboprophylaxis in cancer outpatients.
Blood 2008 May 15;111(10):4833.

Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B; on behalf of the EXTEND Study Group.
Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran.
Thromb Res 2008 May 14. [Epub ahead of print]

Hermosillo AJ, Spinler SA.
Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?
Ann Pharmacother 2008 May 13. [Epub ahead of print]

Devine EB, Hopefl AW, Wittkowsky AK.
Adherence to guidelines for the management of excessive warfarin anticoagulation.
J Thromb Thrombolysis. 2008 May 9. [Epub ahead of print]

Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Ginsberg JS.
Determinants of health-related quality of life during the two years following deep venous thrombosis.
J Thromb Haemost 2008 May 3. [Epub ahead of print]

Rubboli A, Halperin JL, Juhani Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Fat Tse H, Verheugt FW, Lip GY.
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Ann Med 2008 May 2:1-9. [Epub ahead of print]

Legnani C, Palareti G, Cosmi B, Cini M, Tosetto A, Tripodi A; for the PROLONG Investigators (on behalf of FCSA Italian Federation of Thrombosis Centers)
Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG stu
Haematologica 2008 Apr 28. [Epub ahead of print]

Magee K, Campbell S, Moher D, Rowe B.
Heparin versus placebo for acute coronary syndromes.
Cochrane Database Syst Rev 2008 Apr 16;(2):CD003462.

Akl E, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann H.
Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
Cochrane Database Syst Rev 2008 Apr 16;(2):CD006650.

Lassen MR, Dahl O, Mismetti P, Zielske D, Turpie AG.
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study.
J Am Coll Cardiol 2008 Apr 15;51(15):1498-504.

Prandoni P, Samama MM.
Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients.
Br J Haematol 2008 Apr 13; [Epub ahead of print]

The RE-MOBILIZE Writing Committee.
The Oral Thrombin Inhibitor Dabigatran Etexilate vs the North American Enoxaparin Regimen for the Prevention of Venous Thromboembolism after Knee Arthroplasty Surgery.
J Arthroplasty 2008 Apr 11. [Epub ahead of print]

Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F, Cook DJ, Schünemann HJ.
Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis.
Cancer 2008 Apr 10; [Epub ahead of print]

Baglin T.
Venous thromboembolism in hospitalised patients: a public health crisis?
Br J Haematol 2008 Apr 10; [Epub ahead of print]

Meiltz A, Zimmermann M, Urban P, Bloch A; on behalf of the Association of Cardiologists of the Canton of Geneva.
Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world.
Europace 2008 Apr 10; [Epub ahead of print]

Edwards JZ, Pulido PA, Ezzet KA, Copp SN, Walker RH, Colwell CW Jr.
Portable Compression Device and Low-Molecular-Weight Heparin Compared With Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Joint Arthroplasty.
J Arthroplasty 2008 Apr 1. [Epub ahead of print]

Jowett S, Bryan S, Mahé I, Brieger D, Carlsson J, Kartman B, Nevinson M.
A multinational investigation of time and traveling costs in attending anticoagulation clinics.
Value Health 2008 Mar-Apr;11(2):207-12

Karnicki K, Leadley RJ Jr, Baxi S, Peterson T, Wysokinski W, McBane RD 2nd.
Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Thromb Haemost 2008 Apr;99(4):759-66.

Abdelhafiz AH, Wheeldon NM.
Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice.
Am J Geriatr Pharmacother 2008 Mar;6(1):1-11.

Bullock-Palmer RP, Weiss S, Hyman C.
Innovative approaches to increase deep vein thrombosis prophylaxis rate resulting in a decrease in hospital-acquired deep vein thrombosis at a tertiary-care teaching hospital.
J Hosp Med 2008 Mar;3(2):148-55.

Stangier J.
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Clin Pharmacokinet 2008;47(5):285-95.

Paskauskas S, Pundzius J, Barauskas G.
Venous thromboembolism and prophylaxis in cancer patients.
Medicina (Kaunas) 2008;44(3):175-81.